Table 2.

Sequential Testing Results in Each Database for Persons 12–64 Years of Age by AESI and Vaccine Brand Following All Doses in the Optum, HealthCore, and CVS Health Databases.

AESI	Vaccine Brand	Optum				HealthCore				CVS Health
		Number of Doses	Observed AESI	Observed Person-Time (Years)	RR	Number of Doses	Observed AESI	Observed Person-Time (Years)	RR	Number of Doses	Observed AESI	Observed Person-Time (Years)	RR
Acute Myocardial Infarction	BNT162b2	5,019,206	287	286,238	0.94	7,071,320	402	395,810	0.89	3,924,085	253	212,161	1.08
	mRNA-1273	2,563,618	214	181,507	1.03	3,959,087	314	277,351	0.91	2,061,250	191	136,166	1.15
	Ad26.COV2.S	244,144	22	17,097	1.05	410,337	47	28,898	1.18	182,559	23	12,830	1.41
Deep Vein Thrombosis	BNT162b2	5,008,608	554	330,015	0.88	7,056,415	784	471,740	0.84	3,914,571	510	257,894	0.97
	mRNA-1273	2,557,370	372	181,145	0.90	3,949,117	622	284,292	0.90	2,055,345	373	144,691	1.05
	Ad26.COV2.S	243,754	43	17,080	1.08	409,584	66	29,015	0.89	182,160	44	12,987	1.34
Pulmonary Embolism	BNT162b2	5,012,070	491	330,248	1.05	7,061,704	703	480,890	1.28	3,917,508	419	263,292	1.33
	mRNA-1273	2,559,512	287	181,298	0.93	3,952,765	484	291,066	1.19	2,057,241	290	148,429	1.36
	Ad26.COV2.S	243,960	41	17,093	1.39	409,983	53	29,172	1.23	182,303	42	13,061	2.14
Disseminated Intravascular Coagulation	BNT162b2	5,023,766	<11	331,025	0.68	7,077,841	20	454,338	1.04	3,928,054	<11	246,883	0.75
	mRNA-1273	2,566,651	<11	181,806	1.13	3,963,914	<11	270,691	0.67	2,064,003	<11	136,647	0.78
	Ad26.COV2.S	244,438	0	17,127	0.00	410,855	<11	28,770	2.04	182,820	<11	12,854	0.00
Non-hemorrhagic Stroke	BNT162b2	5,021,535	155	330,879	0.84	7,074,745	203	463,405	0.86	3,926,134	133	246,760	1.04
	mRNA-1273	2,565,297	102	181,710	0.82	3,961,715	163	277,911	0.91	2,062,693	92	136,557	1.03
	Ad26.COV2.S	244,335	<11	17,120	0.33	410,643	25	28,933	1.24	182,699	<11	12,846	0.59
Hemorrhagic Stroke	BNT162b2	5,023,270	49	330,993	0.93	7,077,241	65	463,570	1.09	3,927,632	50	252,624	1.29
	mRNA-1273	2,566,330	39	181,783	1.13	3,963,522	46	278,041	1.05	2,063,645	20	140,920	0.75
	Ad26.COV2.S	244,425	<11	17,126	0.86	410,812	<11	28,945	1.21	182,798	<11	12,946	0.77
Immune Thrombocytopenia	BNT162b2	5,021,182	107	430,376	0.81	7,073,917	192	624,983	1.26	3,925,794	107	342,468	1.28
	mRNA-1273	2,565,158	89	234,123	1.12	3,961,662	124	375,130	1.21	2,062,548	77	191,084	1.49
	Ad26.COV2.S	244,341	13	25,382	1.53	410,664	<11	43,453	0.81	182,739	11	19,418	2.03
Myocarditis/Pericarditis	BNT162b2	5,021,652	264	430,415	1.73	7,074,944	322	625,077	1.83*	3,926,219	243	342,505	2.47*
	mRNA-1273	2,565,543	125	234,160	1.33	3,962,191	191	375,181	1.62	2,062,979	118	191,126	1.92
	Ad26.COV2.S	244,356	14	25,382	1.27	410,677	25	43,455	1.63	182,728	<11	19,417	1.44
Guillain-Barré Syndrome	BNT162b2	5,023,855	13	430,610	1.21	7,078,019	11	499,735	1.11	3,928,151	<11	282,110	1.05
	mRNA-1273	2,566,689	<11	234,266	1.40	3,963,994	<11	343,807	0.85	2,064,026	<11	179,364	1.34
	Ad26.COV2.S	244,448	<11	25,392	6.53	410,867	<11	42,672	8.53	182,825	<11	19,176	2.31
Bell's Palsy	BNT162b2	5,538,066	422	474,536	0.88	7,758,783	601	684,770	0.98	4,399,969	360	382,934	1.10
	mRNA-1273	2,844,137	259	259,242	0.86	4,338,960	415	410,068	1.01	2,321,435	241	214,305	1.17
	Ad26.COV2.S	268,766	49	27,862	1.49	446,543	74	47,119	1.46	206,493	25	21,824	1.13
Encephalo- myelitis/ Encephalitis	BNT162b2	5,541,351	18	474,821	1.48	7,763,335	18	640,440	1.43	4,402,681	11	347,757	1.67
	mRNA-1273	2,846,033	<11	259,415	0.90	4,341,907	13	374,979	1.82	2,323,255	<11	187,781	1.89
	Ad26.COV2.S	268,944	<11	27,881	1.26	446,815	<11	46,229	6.48	206,652	<11	21,177	0.00
Anaphylaxis	BNT162b2	6,076,878	26	32,601	4.48*	8,627,389	42	46,920	7.50*	4,989,398	39	27,296	10.86*
	mRNA-1273	3,135,659	20	16,852	7.64*	4,836,013	33	26,284	11.88*	2,644,637	20	14,465	12.40*
	Ad26.COV2.S	297,441	<11	1,525	4.05	500,220	<11	2,580	10.47	236,326	<11	1,234	20.41
Transverse Myelitis	BNT162b2	5,023,831	<11	430,608	0.70	7,078,019	<11	511,896	0.81	3,928,148	<11	326,988	1.26
	mRNA-1273	2,566,683	<11	234,265	0.89	3,963,962	<11	354,221	0.70	2,064,016	<11	179,776	1.30
	Ad26.COV2.S	244,445	<11	25,392	5.05	410,867	<11	42,968	7.41	182,822	<11	19,184	3.82
Narcolepsy	BNT162b2	5,020,198	133	430,293	0.74	7,072,100	237	624,826	1.07	3,924,967	132	342,395	1.35
	mRNA-1273	2,564,481	83	234,066	0.78	3,960,148	143	374,990	1.02	2,061,955	78	191,032	1.36
	Ad26.COV2.S	244,273	12	25,374	1.01	410,465	16	43,433	0.94	182,663	<11	19,410	1.63
Appendicitis	BNT162b2	5,016,516	617	429,981	1.09	7,068,850	744	598,204	1.01	3,922,860	449	326,528	1.32
	mRNA-1273	2,563,415	295	233,967	0.95	3,959,186	428	354,296	1.08	2,061,316	219	179,531	1.27
	Ad26.COV2.S	244,128	51	25,358	1.39	410,355	50	42,933	0.97	182,566	37	19,156	1.84
Common Thromboses with Thrombocytopenia	BNT162b2	5,022,754	86	330,958	1.03	7,076,575	94	473,091	1.08	3,927,012	81	258,722	1.31
	mRNA-1273	2,566,085	48	181,765	0.86	3,962,989	63	285,291	0.97	2,063,270	49	145,252	1.15
	Ad26.COV2.S	244,393	<11	17,124	1.46	410,783	13	29,098	1.80	182,766	<11	13,029	0.98
Unusual Site Thromboses (Broad) with Thrombocytopenia	BNT162b2	5,023,838	11	331,030	1.42	7,077,950	11	463,616	1.34	3,928,087	<11	212,417	0.96
	mRNA-1273	2,566,664	<11	181,806	0.99	3,963,936	<11	278,070	0.68	2,063,992	<11	136,353	0.92
	Ad26.COV2.S	244,449	<11	17,127	1.95	410,861	<11	28,949	4.46	182,821	<11	12,848	2.34

*indicates the AESI for the specific brand has signaled in the data.

Abbreviation: AESI, adverse event of special interest; RR, rate ratio.

Results presented for Optum data through 1/22/2022, HealthCore data through 1/7/2022, CVS data through 12/31/2021.

The number of sequential tests conducted varied by database and AESI.

Cell sizes 1–10 were masked for confidentiality.